Progyny, Inc. - Common Stock (PGNY)

What Happened? Shares of fertility benefits company Progyny (NASDAQ:PGNY) jumped 17.5% in the afternoon session after the company reported first-quarter 2026...

Progyny (PGNY) Q1 2026 Earnings Call Transcript

Fertility benefits company Progyny (NASDAQ:PGNY) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 1.4% year on year to $328.5...

Fertility benefits company Progyny (NASDAQ:PGNY) will be reporting results this Thursday after the bell. Here’s what to expect. Progyny beat analysts’ revenu...

Although the S&P 500 is down 2.1% over the past six months, Progyny’s stock price has fallen further to $17.17, losing shareholders 16.6% of their capital. T...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a co...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Shares of fertility benefits company Progyny (NASDAQ:PGNY) fell 22% in the afternoon session after it issued a weak financial outlook for 2026 that overshadowed its fourth-quarter results. 

Progyny (PGNY) Q4 2025 Earnings Call Transcript

Fertility benefits company Progyny (NASDAQ:PGNY) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 6.7% year on year to $318.4 million. On the other hand, next quarter’s revenue guidance of $325.5 million was less impressive, coming in 5.1% below analysts’ estimates. Its non-GAAP profit of $0.48 per share was 19.9% above analysts’ consensus estimates.

Fertility benefits company Progyny (NASDAQ:PGNY) will be reporting earnings this Thursday after market close. Here’s what to look for.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.

Shares of fertility benefits company Progyny (NASDAQ:PGNY) jumped 3.3% in the afternoon session after Citizens upgraded the fertility benefits company's stock from Market Perform to Market Outperform, setting a price target of $30.00. 

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

Shares of fertility benefits company Progyny (NASDAQ:PGNY) jumped 4.9% in the morning session after an analyst at Keybanc maintained a positive rating on the stock and raised its price target. 

Over the past six months, Progyny has been a great trade, beating the S&P 500 by 5.2%. Its stock price has climbed to $25.68, representing a healthy 16.4% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.